There were 27 MACE-3 (cardiovascular death, heart attack, or stroke) events in participants randomized to retatrutide and 23 in those randomized to placebo, resulting in a hazard ratio of 1.12 (95.0% CI: 0.64 to 1.96)
Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-treatment analysis of a randomised placebo-controlled trial
For the best outcomes, the most effective maintenance plan after stopping treatment should also include other GLP-1 promoting behaviors like exercise, adequate sleep, and stress management
Body measurements Weight isnt the only indicator of success
Do GLP-1 drugs increase SCFAs or diversity
The nervous system responds by breaking down muscle tissue for energy